Eli Lilly 2025 Outlook Raised as Mounjaro, Zepbound Sales Soar
Eli Lilly & Co (NYSE:LLY) has done it again, posting another quarter of top of the line results as the company increases its 2025 guidance on blockbuster sales from Mounjaro and Zepbound, the firm’s top two drug discoveries to date for the treatment of diabetes and weight loss. The pharmaceutical behemoth crushed second-quarter views as … Read more


